Navigation Links
VLST Corporation Announces In-licensing Agreement with Pfizer for Anti-CD40 Monoclonal Antibody
Date:8/31/2012

SEATTLE, Aug. 31, 2012 /PRNewswire/ -- VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for cancer and autoimmune and inflammatory disorders, today announced an in-licensing agreement with Pfizer Inc. for an anti-CD40 monoclonal antibody.

(Logo: http://photos.prnewswire.com/prnh/20120831/SF65959LOGO)

CP-870,893 is a potent CD40 agonist that has been evaluated in a number of preclinical and clinical trials to date. These studies have determined the safety profile, pharmacokinetics and pharmacodynamic parameters of CD40-mediated immune activation as well as the maximum tolerated dose of the antibody.  VLST plans to advance this compound into efficacy studies in an oncology setting.  VLST is currently evaluating multiple clinical opportunities.  Under the terms of the agreement, Pfizer will retain co-exclusive rights to CP-870,893 in the oncology vaccine field.

"We are excited to in-license this promising compound. With the transfer of the IND from Pfizer, we will accelerate the development of our clinical strategy and expand our focus in immunotherapy to include oncology," said Martin Simonetti, President and Chief Executive Officer of VLST.  "Our recent financing will help support our Phase 2 clinical efforts."

"This agreement with VLST is yet another example of how Pfizer is executing against its portfolio management goals in oncology while finding a positive way forward for those compounds leaving our pipeline," said Garry Nicholson, President and General Manager of Pfizer Oncology.  "VLST's expertise in immunotherapy makes the company a strong partner to continue the development of this compound and potentially deliver a new therapy to patients with cancer."

VLST completed a tranche of the Series B financing of $5 million in June 2012. The financing was led by ARCH Venture Partners and included OVP Venture Partners, WRF Capital and Versant Ventures.

About VLST
VLST Corporation is a privately held biotechnology company dedicated to the streamlined discovery and development of novel therapeutics for the treatment of cancer and inflammatory and autoimmune disorders. The VLST approach combines novel bioinformatics and cutting-edge proteomics to provide a rapid and rational approach to identifying new targets for the development of novel biologic therapies.  The VLST discovery platform has primary applications for the treatment of cancer and inflammatory and autoimmune diseases.  For more information, please visit www.vlstcorp.com.

Contact:
Julie Rathbun
Rathbun Communications, Inc.
julie@rathbuncomm.com
(206) 769-9219


'/>"/>
SOURCE VLST Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MGC Diagnostics Corporation Completes Sale of New Leaf Business Assets to Life Time - The Healthy Way of Life Company
2. MGC Diagnostics Corporation Reports Third Quarter Fiscal Year 2012 Operating Results
3. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
4. The Hygenic Corporations Custom Rubber Solutions Solve Industry Problems
5. MGC Diagnostics Corporation to Report Third Quarter Fiscal 2012 Financial Results on Thursday, August 30, 2012
6. Kewaunee Scientific Corporation Declares Quarterly Dividend
7. Siemens Healthcare Enters into Definitive Agreement to Acquire Penrith Corporation
8. MGC Diagnostics Corporation Launches New Corporate Website and Unveils New Logo
9. Comprehensive Care Corporation Names Jairo Estrada Senior Management Advisor To Assist in Growing the Companys New Pharmacy Initiatives
10. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Masimo Corporation in Connection with Executive Compensation
11. SpineMark Corporation Partners with PhDx and Millennium Environmental to Create an ISO type Spine Protocol Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
(Date:3/27/2017)... March 27, 2017  BERG, a biopharmaceutical ... biological research approach, today announced that the ... discovery of new data using a cold-induced ... fat metabolism. Joslin Diabetes Center led the ... platform for analysis of samples.  The findings ...
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The TouchPoint Solution’s ... the Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch about the ... , Project Entrepreneur’s second annual venture competition ignites bold ideas by providing women access ...
(Date:3/27/2017)... , ... March 27, 2017 , ... The Case Management ... of Directors on June 30, 2017. CMSA’s membership has elected their upcoming President-Elect, ... our current Military Advisory position, a new VA Advisory position has also been added ...
(Date:3/27/2017)... Birmingham, Clarkston, and Lake Orion, Michigan (PRWEB) , ... ... ... can affect weight loss results. The comprehensive weight management program at Women’s ... begins with an initial evaluation and physical exam. The specialists at ...
(Date:3/27/2017)... ... March 27, 2017 , ... Kwalu, a leading provider of ... row; they are the recipient of the prestigious “Best Overall Design Strategy in ... at Design Connections 2017. Top A&D professionals from leading firms, furniture manufacturers and ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer Society , ... more than 95%. Once the cancer spreads to other organs, bones, or lymph nodes, ... how to avoid this latter group, tune in to Lifestyle Magazine on ...
Breaking Medicine News(10 mins):